TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04948554

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Administered Subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Administered Subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Administered Subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Administered Subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Administered Subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Administered Subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05163821

Intervention type: DIAGNOSTIC_TEST
Intervention: Manchester Somali Cognitive Assessment Tool
Description: Cognitive screen for dementia

Intervention type: DIAGNOSTIC_TEST
Intervention: ACE-III Somali Translation
Description: Cognitive screen for dementia
Study: NCT06300476

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWK006
Description: Subretinal administration of gene therapy vector JWK006 to one eye.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWK006
Description: Subretinal administration of gene therapy vector JWK006 to one eye.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JWK006
Description: Subretinal administration of gene therapy vector JWK006 to one eye.
Study: NCT06037694

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Free Gingival Graft
Description: Implant site with insufficient dimensions of KM will be covered by a conventional free gingival graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 'Mesh Free Gingival Graft
Description: Implant site with insufficient dimensions of KM will be covered by a expanded meshed free gingival graft.
Study: NCT06260267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbiota suspension
Description: Microbiota suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microbiota capsule
Description: Microbiota capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension
Description: Placebo suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule
Study: NCT04142320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop rTMS
Description: Delivers patterned magnetic stimulation in closed-loop fashion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: open-loop rTMS
Description: Delivers patterned magnetic stimulation in open-loop fashion

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: Delivers placebo magnetic stimulation
Study: NCT06162845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A smartphone based application free to download from the google play and iphone store to provide auditory and visual cues and counting for number of perscribed pelvic floor muscle contractions
Description: Use of a smartphone-based home exercise application for pelvic floor muscle exercises with visual and auditory feedback for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Paper-based home exercise program for pelvic floor muscle exercise
Description: Written instructions on a piece of paper for 10 repetitions of pelvic floor contraction endurance holds and 10 repetitions of pelvic floor quick contractions performed three times per day.
Study: NCT04316442

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: STI-6129
Description: Four cycles of intravenous infusion of STI-6129 will be given (one infusion every four weeks).
Study: NCT05212324

Intervention type: PROCEDURE
Intervention: widening of first web space
Description: widening of first web space by flaps, tendon transfer to extensor policis longus tendon, fractional lengthening of flexor policis longus tendon
Study: NCT05809024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Hormone receptor positive,HER2 negative participants will receive letrozole as neoadjuvant endocrine therapy，if don't work, CDK4/6 Inhibitor was added.
Study: NCT05985473

Intervention type: OTHER
Group type: OTHER
Intervention: audiological measurements
Description: audiological measurements

Intervention type: OTHER
Group type: OTHER
Intervention: Objective and subjective audiological measurements
Description: Objective and subjective audiological measurements

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the denoising methods REFINED
Description: Evaluation of the denoising methods REFINED
Study: NCT04964297

Intervention type: DEVICE
Group type: OTHER
Intervention: Obtaining bowel gas samples
Description: The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings.

Intervention type: DEVICE
Group type: OTHER
Intervention: Obtaining bowel gas samples
Description: The Perf-AlertTM prototype consists of a 15 x 13 x 7 unit containing gas sensors and valves, a small box containing a one-way, ultra-low pressure pump, user controls (buttons), and software algorithms, which control the operation of the device. It is used in conjunction with a single-use, disposable kit of sterile tubing and filters used for sample collection. The sensing unit will be connected via a sterile tube/filter set to any trocar port in use during the procedure. At specific time points during surgery, a one-way valve will be opened, and the unit's pump turned on and withdrawing a small amount of gas from the abdominal cavity. The system is configured that sample collection, transport, analysis, and feedback occur in a single step such that sample collection and sensor feedback occur in real-time. A standard laptop running an analytical software program is connected to the unit to record and log sensor readings.
Study: NCT05432323

Intervention type: BEHAVIORAL
Intervention: Multi-family therapy
Description: 8 sessions of Multi-family therapy of 3 hours each during 24 weeks

Intervention type: BEHAVIORAL
Intervention: Multi-family therapy
Description: 8 sessions of Multi-family therapy of 3 hours each during 24 weeks
Study: NCT04038619

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Undergo FMT via colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: Given PO
Study: NCT05716906

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg gummy 30 min before bedtime for 2 consecutive nights
Study: NCT06647732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg, administered twice daily from Day 1 to Day 28 (D1-D28)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m², administered once a week during Cycle 1 (C1), and on Day 1 (D1) of Cycles 2-6 (C2-C6)
Study: NCT05048212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given by IV
Study: NCT05164731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third does was given 3, 4, 5 or 6 months after two doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
Description: the third does was given 3, 4, 5 or 6 months after two doses
Study: NCT06512454

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT05778331

Intervention type: PROCEDURE
Intervention: Antagonist protocol for induction of ovulation
Description: Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality

Intervention type: PROCEDURE
Intervention: Antagonist protocol for induction of ovulation
Description: Full labs will be revised to exclude women with any chronic disease. Ultrasound to exclude any anatomical uterine problem.HSG.Women who will be categorized as Poseidon group 3 and Poseidon group 4.They will be given after that antagonist protocol with dose of HMG/FSH 300-450 I.U. per day: (Gonapure 150 I.U -follicle stimulating hormone FSH preparation of recombinant DNA technology- MinaPharm pharmaceuticals-Egypt) will be given from 2nd day of menstruation per day as starting dose then on 7th day (Cetrotide 0.25 -Cetrorelix, an anti-gonadotropin releasing hormone- MERCK SORONO-Germany) will be given daily till triggering . US will be done to evaluate follicular size from 7th day if it will be 1.8 cm or more for at least 2 follicles then (Chorimon 5000 i.u-Choriogonadotropin Alfa-IBSA-Switzerland )of total dose 10000 I.U. will be given then ovum pick up with be done after 35 h of triggering ovulation .Assessment of embryo quality
Study: NCT05583851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Smartphone app guided and manualized version of acceptance and commitment therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation Active Control
Description: Set of 11 public seminar videos regarding depression and anxiety. Each are 15 minutes long.
Study: NCT05334823

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pCAR-19B cells
Description: Drug: pCAR-19B cells； Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT06080594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity exercise training
Description: Eight sessions of high-intensity interval exercise using a single-leg cycle ergometer are conducted on separate days over a 2-week period.
Study: NCT06017817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Anti-infective photodynamic therapy for plaque-induced oral conditions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Anti-infective photodynamic therapy for plaque-induced oral conditions

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene instructions
Description: Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene instructions
Description: Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene instructions
Description: Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene instructions
Description: Standard oral hygiene instructions for electric toothbrushing, interdental brush, and dental floss use

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing (SRP
Description: non-surgical anti-infective treatment by scaling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP
Description: non-surgical anti-infective treatment by scaling and root planing

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical anti-infective peri-implantitis treatment
Description: surgical anti-infective peri-implantitis treatment

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical anti-infective peri-implantitis treatment
Description: surgical anti-infective peri-implantitis treatment
Study: NCT06648005

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the spinal manipulative therapy combined brace
Description: Besides bracing, the SMTB group was treated with spinal manipulative therapy. If discomfort occurs, we will stop the treatment immediately. Spinal manipulation is performed twice a week. Two doctors with 10 years of clinical experience will perform all examinations and manipulations. Intensive training was given to the physiotherapists in spinal manipulation. The doctors took the medical history of all participants and performed a clinical examination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: brace
Description: Subjects were requested to wear orthosis 23 hrs/d and 1 hr for personal hygiene and exercise activities. The subjects were treated for 12 months. In addition, interview for compliance was launched when the subjects came to the scoliosis clinic for follow-up visits.
Study: NCT06649474

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: assess the serum HMGB1 concentrations before and after an oxaliplatin-based chemotherapy
Description: assess the serum HMGB1 concentrations
Study: NCT06648174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set); and 33 weeks of pregnancy to before delivery (second set) respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 7-14 days after starting to wear), the investigators will provide glucose monitor reports. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor reports was given approximately 7-14 days after starting to wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor
Description: Participants will receive a set of continuous glucose monitor (CGM) at 24-32 weeks of pregnancy (first set); and 33 weeks of pregnancy to before delivery (second set) respectively.~CGM wearing instruction will be provided before the first wearing at 24-32 weeks of pregnancy. After completing the first wearing (approximately 7-14 days after starting to wear), the investigators will provide glucose monitor reports. The second CGM was worn from the 33rd week of pregnancy to before delivery, and another glucose monitor reports was given approximately 7-14 days after starting to wear.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perinatal nursing care for gestational diabetes
Description: Individual nursing care and consultation for women with gestational diabetes mellitus, including glucose monitor suggestions, dietary suggestions, emotional support, breastfeeding support at 24-32 weeks of pregnancy, 33 weeks of pregnancy to before delivery, and 4-12 weeks postpartum.

Intervention type: OTHER
Group type: OTHER
Intervention: Blood glucose meters (BGM)
Description: Participants are required to use blood glucose meters (BGM) at 24-32 weeks of pregnancy and 33 weeks to before delivery. After 7-14 days of glucose monitoring at 24-32 weeks of pregnancy, glucose monitor reports will be given to the participants. After the 7-14 days of glucose monitoring at 33 weeks to before delivery, another glucose monitor reports will be given to the participants.
Study: NCT05551520

Intervention type: DEVICE
Group type: OTHER
Intervention: Normative
Description: ImPACT will be administered at baseline testing

Intervention type: DEVICE
Group type: OTHER
Intervention: Reliability
Description: ImPACT will be administered again within 60 days of baseline test
Study: NCT06387706

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified web-based pain management Program
Description: Gamified Program Development: The project aims to create a Gamified web-based pain management Program (GAP) tailored for older adults with chronic pain, enhancing engagement through gaming elements.~Inclusive Design Process: Older adults with chronic pain will actively participate in developing GAP, providing valuable feedback throughout the process.~Pilot Study Design: A pre and post study design will be employed, with a small pilot group of 4 participants to offer diverse perspectives in the program's development.~Educational Content \& Activities: GAP will feature interactive educational content on pain effects, medication, non-drug treatments, and exercises, delivered through a mobile-friendly web platform.
Study: NCT02361554

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept with SensSight Deep Brain Stimulation System
Description: Placement of Deep brain stimulation System for treatment of chronic auditory hallucinations in treatment-resistant schizophrenia
Study: NCT05900089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR0302
Description: SHR0302 will be administered orally as tablet. SHR0302 treatment will be continued until disease progression or intolerant adverse reactions
Study: NCT06389292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisaftoclax (APG-2575)
Description: QD, oral administration, every 28 days for a dosing cycle.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: QD, oral administration, every 28 days for a dosing cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine Injection
Description: QD, hypodermic or intravenous injection, D1-7 in 28-day cycle.
Study: NCT05124080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: All participants will receive 6 mg of Deucravacitinib daily.
Study: NCT06077552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pyramidal training by treadmill
Description: pyramidal training by treadmill for 40 minutes per session three sessions per week for eight weeks in addition to the diet health advises